Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nithya Ramnath

Showing results (1-10 of 142) with videos related to

Pageof 15
Sort By:
Translational Cancer Research|October 7, 2017
The "liquid biopsy" in non-small cell lung cancer - not quite ready for prime time useAngel Qin, Nithya Ramnath
Clinical Lung Cancer|July 28, 2009
Progress in the treatment of metastatic non-small-cell lung cancer: slow but steady!Nithya Ramnath, Ramaswamy Govindan
Translational Lung Cancer Research|November 6, 2018
Targeting IL22: a potential therapeutic approach for Kras mutant lung cancer?Frank D Weinberg, Nithya Ramnath
Current Oncology Reports|January 31, 2004
Matrix metalloproteinase inhibitorsNithya Ramnath, Patrick J Creaven
The New England Journal of Medicine|January 24, 2020
Fluorouracil-Induced HyperpigmentationJordan K Schaefer, Nithya Ramnath
The Oncologist|June 20, 2023
Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to ImmunotherapyAjoy Oommen John, Nithya Ramnath
Cancers|August 21, 2019
Reactive Oxygen Species in the Tumor Microenvironment: An OverviewFrank Weinberg, Nithya Ramnath, Deepak Nagrath
Frontiers in Oncology|October 21, 2015
Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future DirectionsZhuo Zhang, Nithya Ramnath, Sunitha Nagrath
Cancers|April 3, 2021
Immunotherapy for <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising ApproachesKamya Sankar, Sunitha Nagrath, Nithya Ramnath
Translational Lung Cancer Research|July 8, 2024
Pros and cons of subcutaneous (SC) versus intravenous (IV) administration of immune checkpoint inhibitors in non-small cell lung cancerJulie Moeller, Michael D Green, Nithya Ramnath
Pageof 15

Showing results (1-10 of 142) with videos related to

Sort By:
Pageof 15
Translational Cancer Research|October 7, 2017
The "liquid biopsy" in non-small cell lung cancer - not quite ready for prime time useAngel Qin, Nithya Ramnath
Clinical Lung Cancer|July 28, 2009
Progress in the treatment of metastatic non-small-cell lung cancer: slow but steady!Nithya Ramnath, Ramaswamy Govindan
Translational Lung Cancer Research|November 6, 2018
Targeting IL22: a potential therapeutic approach for Kras mutant lung cancer?Frank D Weinberg, Nithya Ramnath
Current Oncology Reports|January 31, 2004
Matrix metalloproteinase inhibitorsNithya Ramnath, Patrick J Creaven
The New England Journal of Medicine|January 24, 2020
Fluorouracil-Induced HyperpigmentationJordan K Schaefer, Nithya Ramnath
The Oncologist|June 20, 2023
Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to ImmunotherapyAjoy Oommen John, Nithya Ramnath
Cancers|August 21, 2019
Reactive Oxygen Species in the Tumor Microenvironment: An OverviewFrank Weinberg, Nithya Ramnath, Deepak Nagrath
Frontiers in Oncology|October 21, 2015
Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future DirectionsZhuo Zhang, Nithya Ramnath, Sunitha Nagrath
Cancers|April 3, 2021
Immunotherapy for <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising ApproachesKamya Sankar, Sunitha Nagrath, Nithya Ramnath
Translational Lung Cancer Research|July 8, 2024
Pros and cons of subcutaneous (SC) versus intravenous (IV) administration of immune checkpoint inhibitors in non-small cell lung cancerJulie Moeller, Michael D Green, Nithya Ramnath
Pageof 15